XBIO
Xenetic Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Ample Liquidity
High Gross Profit Margin
Gap Up
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About XBIO
Xenetic Biosciences, Inc.
A biotech company that develops next-generation immunotherapies and targeted oncology therapies
945 Concord Street, Framingham, Massachusetts 01701
--
Xenetic Biosciences, Inc., was founded in Nevada in August 2011. It is a clinical-stage biopharmaceutical company focused on the discovery, research and development of new generation biopharmaceuticals and novel orphan tumor treatments that may contribute to the improvement of human health worldwide.
Company Financials
EPS
XBIO has released its 2025 Q2 earnings. EPS was reported at -0.45, versus the expected -0.79, beating expectations. The chart below visualizes how XBIO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
XBIO has released its 2025 Q3 earnings report, with revenue of 1.03M, reflecting a YoY change of 67.19%, and net profit of -509.94K, showing a YoY change of -16.78%. The Sankey diagram below clearly presents XBIO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
